Who is sponsoring NCT03982420?

NCT03982420 is sponsored by Silk Road Medical.

What drugs are being tested in NCT03982420?

Interventions in NCT03982420: Transcarotid Revascularization (TCAR).

What condition does NCT03982420 study?

NCT03982420 studies Carotid Artery Diseases, Carotid Atherosclerosis, Carotid Stenosis, Carotid Artery Plaque, Carotid Disease.

Is NCT03982420 still recruiting?

NCT03982420 is currently completed. Last updated 14 January 2026.

Are results published for NCT03982420?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2026-01-14 · How we verify

NCT03982420: DW-MRI-US

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The ENROUTE Transcarotid Neuroprotection System (ENROUTE Transcarotid NPS) DW-MRI Evaluation

Completed Results posted Last updated 14 January 2026

What this trial tests

trial testing Transcarotid Revascularization (TCAR) in Carotid Artery Diseases in 55 participants. Completed in 19 January 2022.

Timeline

27 June 2019

Primary endpoint
19 January 2022

19 January 2022

Quick facts

Lead sponsor	Silk Road Medical
Status	Completed
Study type	OBSERVATIONAL
Enrollment	55
Start date	27 June 2019
Primary completion	19 January 2022
Estimated completion	19 January 2022
Sites	6 locations across United States, Spain

Drugs / interventions tested

Transcarotid Revascularization (TCAR)

Conditions studied

Carotid Artery Diseases — all drugs for Carotid Artery Diseases →
Carotid Atherosclerosis — all drugs for Carotid Atherosclerosis →
Carotid Stenosis — all drugs for Carotid Stenosis →
Carotid Artery Plaque — all drugs for Carotid Artery Plaque →

Sponsor

Silk Road Medical

Who can join

18 and older, any sex, with Carotid Artery Diseases or Carotid Atherosclerosis. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Incidence of Ipsilateral New White Lesions, by Patient Primary · Between 12-60 hours after procedure end time to 30 days post-procedure.

Number of Participants with new white lesions from baseline (pre-procedure) by Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) between 12-60 hours after procedure end time up to 30 days post-procedure.

Group	Value	95% CI
Single-arm	12

Incidence of Ipsilateral Persistent Lesions, by Patient Primary · 30-days

Number of participants at 30 day post-procedure with persistent ipsilateral new white lesions post-procedure by Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI).

Group	Value	95% CI
Single-arm	3

All Stroke and Neurological Death Secondary · 0 to 30 days

Number of Participants who experienced Stroke or Neurological death between 12-60 hours after procedure end time up to 30 days post-procedure.

Stroke

Group	Value	95% CI
Single-arm	0
Single-arm	55

Neurological Death

Group	Value	95% CI
Single-arm	0
Single-arm	55

Volume of DW-MRI White Lesions Secondary · 30-days

Volume of Persistent new white lesions post-procedure by Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) at 30-Days.

Group	Value	95% CI
Single-arm	0.21	0.02 – 0.98

Location of DW-MRI Lesions Secondary · 30-day

Number persistent new white lesions post-procedure by location by Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) at 30-Days, categorized by location.

Middle Cerebral Artery (MCA) Territory - Persistent 30-day lesion

Group	Value	95% CI
Single-arm	5

Posterior Cerebral Artery (PCA) Territory - Persistent 30-day lesion

Group	Value	95% CI
Single-arm	0

Anterior Cerebral Artery (ACA) Territory - Persistent 30-day lesion

Group	Value	95% CI
Single-arm	0

Rate of Contralateral New White Lesions by Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI), by Patient Secondary · 30-day

Subjects with persistent contralateral new white lesions post-procedure by Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI), at 30-Days.

Group	Value	95% CI
Single-arm	0

Sponsor's own description

The goal of this evaluation is to document the incidence of post procedure DW-MRI lesions (relative to baseline) in patients treated with the transcarotid artery revascularization (TCAR) procedure.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Carotid Artery Diseases

Currently open trials in the same condition.

NCT07296965 — Oral Microbiome in Carotid Atherosclerosis · recruiting
NCT06924593 — Study on the Trans-Carotid Artery Occlusion Shunt System · NA · recruiting
NCT06653387 — A Single-arm, Pivotal Study to Evaluate Acute Device and Technical Success of the CGuard Prime Carotid Stent System When · NA · recruiting
NCT06276374 — Highest Efficacy of Dual Antiplatelet Therapy After Carotid Artery Stenting in High Bleeding Risk Patients · NA · recruiting
NCT06959628 — Study on the Trans-Carotid Artery Occlusion Shunt System Combined With Introducer Sets · NA · recruiting

Other Silk Road Medical trials

Trials by the same sponsor.

NCT06470815 — ROADSTER 3 Extended Follow-up Sub-Study · terminated
NCT05365490 — Post-approval Study of Transcarotid Artery Revascularization in Standard Risk Patients With Significant Carotid Artery D · completed
NCT04881162 — Feasibility Study of the Treatment of Acute Ischemic Stroke Using the NOVIS Transcarotid Neuroprotection System · NA · terminated
NCT02536378 — POST-APPROVAL STUDY of TRANSCAROTID ARTERY REVASCULARIZATION in PATIENTS With SIGNIFICANT CAROTID ARTERY DISEASE · completed
NCT03985774 — The ENROUTE Transcarotid Neuroprotection System (ENROUTE Transcarotid NPS) DW-MRI Study · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03982420 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Silk Road Medical
Last refreshed: 14 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03982420.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing